RxDoctor Payments Data

Vipin Jain, MD

Family Medicine · Indianapolis, INNPI 1801849112

Payments from drug & device makers

$6,850in general payments, 2019–2025

Across 52 payments — averaging $131.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • Novo Nordisk$576
  • GSK$521
  • Pfizer$323
  • Exact Sciences$289
  • Lilly USA, LLC$289
  • plus $959 from 12 others

What the payments were for

  • Consulting fees$3,06245%
  • Travel & lodging$69110%
  • Food & beverage$3,09745%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,850 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$34,217
Medicare patients
115
Services billed
381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin29$38,519
EliquisApixaban33$28,427
FarxigaDapagliflozin Propanediol19$18,964
XareltoRivaroxaban23$12,811
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$6,914
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen262$5,588
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$4,468
Atorvastatin Calcium400$4,359
Ezetimibe26$3,545
Gabapentin170$3,396
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$3,070
Albuterol Sulfate HfaAlbuterol Sulfate128$3,008
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,534
Metformin Hcl217$1,734
Valsartan19$1,581

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$323$28,42733 claims
AstraZenecaFarxiga$3,892$18,96419 claims
GSKTrelegy Ellipta$521$6,91412 claims
Scilex Pharmaceuticals Inc.Colchicine$40$92215 claims
AbbVieSynthroid$122$65813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →